--- title: "From currency hedging to AI pivots: Hong Kong equities point to shifting cross-border flows" type: "News" locale: "en" url: "https://longbridge.com/en/news/294039331.md" description: "Amid fluctuating exchange rates, Hong Kong's broad market equities are undergoing a structural revaluation. From a currency-hedged Japan ETF to traditional companies pivoting to AI data services, the sector highlights how cross-border capital reallocation is reshaping non-core assets in 2026." datetime: "2026-07-28T09:13:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294039331.md) - [en](https://longbridge.com/en/news/294039331.md) - [zh-HK](https://longbridge.com/zh-HK/news/294039331.md) generator: "portal-rs" --- # From currency hedging to AI pivots: Hong Kong equities point to shifting cross-border flows Heading into the latter half of 2026, as the monetary policy paths of major global central banks continue to diverge, specific segments and cross-border assets in the Hong Kong stock market are undergoing a notable capital reshuffling. The recent price actions across this eclectic mix of assets — spanning pharmaceuticals, renewable energy, AI data services, and a Japan-focused hedged ETF — highlight the core tension in the current market: caught between a strong US dollar and regional economic uncertainties, investors are weighing whether to seek defensive sanctuaries or to bet on structural transformation dividends. Against the backdrop of intense currency maneuvers, the defensive nature of cross-border capital flows is particularly evident. The ChinaAMC MSCI Japan Hedged to USD ETF (**3160.HK**) has recently served as a crucial instrument for investors to mitigate yen volatility, reflecting a sustained demand for cross-market hedging. Concurrently, as a prominent offshore RMB-denominated asset for the mainland financial giant, Ping An of China -R (**82318.HK**) has slipped in recent trading sessions with modest volume. Its performance sent the strongest signal yet that southbound capital is adopting a cautious, meeting-by-meeting approach when assessing RMB exchange rate expectations. However, defense is not the only narrative. Driven by the spillover effects of the mainland's technology supply chain restructuring, several traditional enterprises are making aggressive pivots. Footwear retailer C.banner International (**1028.HK**) has filled a void in Hong Kong's AI data services sector by acquiring Benyuan Zhishu. Recent data showed that Benyuan Zhishu posted a net profit surge of over **56%** in 2025 and maintained robust momentum in the first five months of 2026. This transition into a high-growth tech lane, coupled with solar energy operator Tonking New Energy (**1666.HK**) navigating the green transition, and JiaChen Holding (**1937.HK**) grappling with headwinds in the traditional access flooring sector, underscores a severe divergence in how the real economy is weathering current pressures. The pharmaceutical sector is similarly caught in the tension between domestic volume-based procurement pressures and overseas expansion expectations. Consun Pharmaceutical (**1681.HK**) recently spent roughly **HKD 792,000** to repurchase shares, and in July 2026, it received an inaugural "Buy" rating from Everbright Securities, indicating a market repricing of its traditional Chinese medicine growth prospects. Following its inclusion in the Stock Connect program in March 2026, respiratory innovator CF PharmTech (**2652.HK**) began attracting direct mainland liquidity, prompting the company to adjust its board lot size to **100** shares to accommodate shifting trading dynamics. Furthermore, biotech names including Zai Lab (**6988.HK**), GenFleet Therapeutics (**2595.HK**), and Jacobson Pharma (**2633.HK**) — which recently garnered "strong buy" recommendations from analysts — are navigating an increasingly complex global financing environment. Looking ahead, the downside risks to these diverse holdings stem primarily from the potential escalation of global trade barriers and the tightening of macro liquidity. Until the next pivotal regulatory or monetary policy juncture, the underlying cross-border flows within this asset pool will continue to serve as a microcosm of broader global capital reallocation. *This article does not constitute investment advice.* ### Related Stocks - [01681.HK](https://longbridge.com/en/quote/01681.HK.md) - [06988.HK](https://longbridge.com/en/quote/06988.HK.md) - [01937.HK](https://longbridge.com/en/quote/01937.HK.md) - [02633.HK](https://longbridge.com/en/quote/02633.HK.md) - [02595.HK](https://longbridge.com/en/quote/02595.HK.md) - [02652.HK](https://longbridge.com/en/quote/02652.HK.md) - [82318.HK](https://longbridge.com/en/quote/82318.HK.md) - [00108.HK](https://longbridge.com/en/quote/00108.HK.md) - [01028.HK](https://longbridge.com/en/quote/01028.HK.md) - [01666.HK](https://longbridge.com/en/quote/01666.HK.md) ## Related News & Research - [Chinese insurer Ping An’s profit rises 36% on policy sales, investments](https://longbridge.com/en/news/296488170.md) - [PING AN 1H26 Net Profit Up 36.1% to RMB92.585B; Interim DPS Hikes 3.2% to RMB0.98](https://longbridge.com/en/news/296473576.md) - [Ping An Insurance Declares Interim Dividend and Sets Tax Terms for Investors](https://longbridge.com/en/news/296477996.md) - [PING AN Confident of Better Full-Yr NBV Growth; Overseas Policy Gain Tax Impact Nearly Zero](https://longbridge.com/en/news/296570673.md) - [Ping An cuts convertible bond conversion price to HK$ 51.25 after interim dividend payout](https://longbridge.com/en/news/296488345.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**